^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + galunisertib (LY2157299) (Phosphotransferase inhibitor, TGF-β1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
Published date:
07/29/2023
Excerpt:
In the phase II NSCLC cohort (n = 25), patients received 150 mg twice daily galunisertib (14 days on/14 days off dosing schedule for all phases) plus nivolumab at 3 mg/kg (intravenously every 2 weeks)....Six (24%) patients had confirmed partial response (PR) and 4 (16%) had stable disease; 1 additional patient had confirmed PR after initial pseudo-progression. The median duration of response was 7.43 months (95% confidence interval [CI]: 3.75, NR). Among the 7 responders, including the delayed responder, 1 had high PD-L1 expression (≥ 50%).
DOI:
10.1186/s12885-023-11153-1
Trial ID:
